Zidovudine
- Generic Name
- Zidovudine
- Brand Names
- Combivir, Retrovir, Trizivir
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13N5O4
- CAS Number
- 30516-87-1
- Unique Ingredient Identifier
- 4B9XT59T7S
- Background
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
- Indication
Used in combination with other antiretroviral agents for the treatment of human immunovirus (HIV) infections.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Perinatal HIV transmission
- Associated Therapies
- -
Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-03-27
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
- Target Recruit Count
- 452
- Registration Number
- NCT00307151
- Locations
- 🇿🇲
George Clinic CRS, Lusaka, Zambia
🇿🇼UZ-College of Health Sciences, Harare, Zimbabwe
🇮🇳BJ Medical College CRS, Pune, Maharashtra, India
Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients
- Conditions
- HIV Infections
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-10-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 123
- Registration Number
- NCT00273975
- Locations
- 🇿🇦
Boehringer Ingelheim Investigational Site, Tygerberg, South Africa
🇿🇦Groote Schuur Hospital, Cape Town, South Africa
Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-12-26
- Last Posted Date
- 2021-11-02
- Target Recruit Count
- 730
- Registration Number
- NCT00270296
- Locations
- 🇧🇼
Athlone Hosp., BHP Study Clinic, Lobatse Shapiro CRS, Lobatse, Botswana
🇧🇼Princess Marina Hosp., BHP Study Clinic, Gaborone Shapiro CRS, Gaborone, Botswana
🇧🇼Deborah Reteif Hosp., BHP Study Clinic, Mochudi Shapiro CRS, Mochudi, Botswana
When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)
- Conditions
- HIV Infections
- Interventions
- Drug: AbacavirDrug: EfavirenzDrug: LamivudineDrug: Lopinavir/RitonavirDrug: NelfinavirDrug: NevirapineDrug: Zidovudine
- First Posted Date
- 2005-10-06
- Last Posted Date
- 2013-12-04
- Target Recruit Count
- 300
- Registration Number
- NCT00234091
- Locations
- 🇰🇭
National Pediatric Hosp., Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇰🇭Social Health Clinic, Cambodia CIPRA CRS, Phnom Penh, Cambodia
🇹🇭Prapokklao Hosp. CIPRA CRS, Chantaburi, Thailand
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00217503
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
- Conditions
- HIV-Associated Lipodystrophy SyndromeCardiovascular Disease
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00192660
- Locations
- 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia
Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV
- Conditions
- Acquired Immunodeficiency Syndrome
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT00144157
- Locations
- 🇿🇦
Boehringer Ingelheim Investigational Site, Soweto, South Africa
Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection
- Conditions
- HIV InfectionsHepatitis B
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2007-04-24
- Lead Sponsor
- International Antiviral Therapy Evaluation Center
- Target Recruit Count
- 24
- Registration Number
- NCT00127959
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, NH, Netherlands
Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-06-24
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 3300
- Registration Number
- NCT00115648
- Locations
- 🇲🇼
College of Medicine, Blantyre, Malawi
Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2005-05-02
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 175
- Registration Number
- NCT00109590
- Locations
- 🇹🇭
Siriraj Hospital Mahidol University CRS, Bangkok, Bangkoknoi, Thailand
🇹🇭Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand
🇹🇭Chiangrai Prachanukroh Hospital CRS, Chiangrai, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.